Endoscopic Sleeve Gastroplasty
Conditions
Brief summary
Obesity and its related metabolic disorders are increasingly a heavy health burden to many parts of the world. Weight control is a well-known important step in avoiding type 2 diabetes mellitus (T2DM). It is also an essential component for normalizing the blood glucose and preventing macrovascular and microvascular insults to patients with diagnosed T2DM. However, life-style modification, physical exercise and dietary adjustment are ineffective measures which are unlikely to confer adequate and sustainable weight loss for the truly obese. On the other hand, large scale long-term follow-up studies have confirmed the role of bariatric surgery in providing durable weight loss and remarkable improvement on medical comorbidities. Among all the bariatric operations, laparoscopic sleeve gastrectomy (LSG) is currently the most widely adopted procedure worldwide because of its simplicity and effectiveness in weight reduction. However, LSG is not without risk. Staple-line hemorrhage, leakage and stenosis are potentially life-threatening complications. LSG is also costly because of the need for expensive laparoscopic staplers.
Detailed description
A new endoscopic bariatric therapy, namely endoscopic sleeve gastroplasty (ESG), has recently been proposed as a non-surgical procedure for the management of obesity with or without diabetes mellitus. Preliminary data based on single arm series or phase II studies have reported promising short and intermediate term weight control effect. However, whether ESG is a feasible option comparable to LSG in the intermediate term remains an unanswered question. In addition, physical and functional outcomes after ESG were not well documented in most of the reported series. Realizing there is a knowledge gap in applying ESG to patients with morbid obesity, we propose to study and compare the efficacy of weight control and functional outcomes of ESG against conventional LSG. Through this prospective randomized trial, the safety profiles, quality of life and changes in fasting and post-prandial gut hormone secretion after the two procedures will also be assessed and compared. The evidence thus generated shall lay a scientific foundation for ESG which may become an alternative choice for patients who have concerns about complication and irreversibility of most bariatric surgery.
Interventions
PROCEDUREEndoscopic Sleeve Gastroplasty
An oesophageal overtube is then inserted to facilitate passage of the endoscope mounted with Overstitch device. A series of full thickness sutures done with Overstitch in the triangular stitch pattern as mentioned by Lopez-Nava\[29\] will be placed according to the APC markings. The suturing is initiated from the antrum distally and moved proximally towards the gastric fundus. A total of 6 to 8 plications are placed to reduce the gastric lumen. Five sham dressings would also be applied to patient's abdominal wall during the first week to minimize the bias in pain scoring.
PROCEDURELaparoscopic Sleeve Gastrectomy
Sleeve gastrectomy is then performed using lapaorscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up to the angle of His along the left side of the Mid-sleeve tube. Haemostasis of the staple line is secured by suture plication with the Mid-sleeve tube in situ to ensure no compromise of the gastric tube lumen. All the wounds are closed with staples after local anaesthetic infiltration and covered with non-transparent dressings.
Sponsors
Chinese University of Hong Kong
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This study protocol aims to test the hypothesis that endoscopic sleeve gastroplasty (ESG) IS NOT inferior to conventional laparoscopic surgical sleeve gastrectomy (LSG) in terms of weight loss and improvement of glycemic control for Asian obese patients. It also investigates and compares the safety profile, improvement of co-morbidities, functional outcomes and changes in gut hormone profiles between the two bariatric procedures.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. A BMI \> 35 kg/m2 2. A BMI \> 30 kg/m2 with T2DM 3. A BMI\>3 30kg/m2 with 2 or more co-morbidities
Exclusion criteria
1. Significant anaesthetic risk (\> ASA III) 2. History of diabetic ketoacidosis or hyperosmolar coma 3. Uncontrolled T2 DM with HbA1c \> 12% 4. A BMI \> 45 kg/m2 5. Malignancy diagnosed within 5 years 6. Endoscopic findings of any pre-neoplastic/neoplastic lesions, portal hypertensive gastropathy or significant varices 7. Chronic renal failure requiring dialysis 8. Previous upper abdominal surgery (including bariatric surgery) affecting gastroduodenal configuration 9. Major psychiatric illness including major depression and substance abuse 10. Pregnancy or ongoing breast-feeding 11. Inmates
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of excess weight loss | 1 year |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| operative time | during operation | — |
| total blood loss intra-operation | during operation | total blood loss will be recorded in operation record |
| early postoperative pain scores | 7 days | — |
| total weight loss | 1 year | (%TWL) |
| postoperative hospital stay | 30 days | — |
| Percentages of excess weight loss | 1 year | (%EWL) |
| perioperative complications | 30 days | mortality |
Countries
China
Contacts
Primary ContactCandice Lam
Backup ContactJenny Ho
Outcome results
None listed